Clinical Trial

REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors)

Study acronym: REZILIENT3
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the safety and efficacy of zipalertinib in combination with standard first-line platinum-based chemotherapy compared to chemotherapy alone, in patients with locally advanced or metastatic NSCLC with EGFR ex20ins mutations.
Protocol Amendment History 1 change
notable Primary completion pushed: 2026-10-29 -> 2027-05-27 2026-07-31
Trial Details
NCT Number NCT05973773
Lead Sponsor Taiho Oncology, Inc.
Conditions Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation
Enrollment 285 participants
Start Date 2023-12-18
Primary Completion 2027-05-27 (estimated)
Study Completion 2027-05-27 (estimated)
Updated on ClinicalTrials.gov 2026-07-30